[{"id":"353049ea-1a4c-45b8-a1c4-3e6301267194","acronym":"","url":"https://clinicaltrials.gov/study/NCT05393804","created_at":"2022-05-26T16:55:32.011Z","updated_at":"2025-02-25T13:54:28.487Z","phase":"Phase 2","brief_title":"A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant","source_id_and_acronym":"NCT05393804","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" SDC1","pipe":"","alterations":" ","tags":["SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Abecma (idecabtagene vicleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 05/20/2022","start_date":" 05/20/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2025-02-20"},{"id":"70160198-3c38-445a-bd28-c334947e8c40","acronym":"CAR-HiRiSMM","url":"https://clinicaltrials.gov/study/NCT06574126","created_at":"2025-02-27T08:14:40.308Z","updated_at":"2025-02-27T08:14:40.308Z","phase":"Phase 2","brief_title":"Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma","source_id_and_acronym":"NCT06574126 - CAR-HiRiSMM","lead_sponsor":"PETHEMA Foundation","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Carvykti (ciltacabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/30/2024","start_date":" 09/30/2024","primary_txt":" Primary completion: 09/30/2032","primary_completion_date":" 09/30/2032","study_txt":" Completion: 09/30/2032","study_completion_date":" 09/30/2032","last_update_posted":"2024-10-26"},{"id":"6418f96b-4898-467e-b98a-b6ad9306f2dd","acronym":"CARTinNS","url":"https://clinicaltrials.gov/study/NCT04561557","created_at":"2024-05-11T04:25:35.338Z","updated_at":"2024-07-02T16:35:05.599Z","phase":"Phase 1","brief_title":"Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System","source_id_and_acronym":"NCT04561557 - CARTinNS","lead_sponsor":"Tongji Hospital","biomarkers":" CD8 • IL6 • CD4","pipe":"","alterations":" ","tags":["CD8 • IL6 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Fucaso (equecabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 09/22/2020","start_date":" 09/22/2020","primary_txt":" Primary completion: 02/22/2027","primary_completion_date":" 02/22/2027","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2024-05-07"},{"id":"f1cfe322-7c0f-4270-b499-e5b443eefa43","acronym":"CARLOTTA01","url":"https://clinicaltrials.gov/study/NCT05836896","created_at":"2023-05-01T14:03:57.086Z","updated_at":"2024-07-02T16:35:18.546Z","phase":"Phase 1","brief_title":"A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies","source_id_and_acronym":"NCT05836896 - CARLOTTA01","lead_sponsor":"Technische Universität Dresden","biomarkers":" CD31 • SLAMF7","pipe":" | ","alterations":" CD38 positive","tags":["CD31 • SLAMF7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MDC-CAR-BCMA001"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 02/15/2024","start_date":" 02/15/2024","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-02-20"},{"id":"34044c3f-866c-4f4c-90fc-aa39c3bd8a17","acronym":"","url":"https://clinicaltrials.gov/study/NCT05976555","created_at":"2024-01-16T18:18:52.892Z","updated_at":"2024-07-02T16:35:23.383Z","phase":"Phase 1","brief_title":"Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma","source_id_and_acronym":"NCT05976555","lead_sponsor":"Medical College of Wisconsin","biomarkers":" TGFB1","pipe":"","alterations":" ","tags":["TGFB1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2024-01-15"},{"id":"99616051-22a3-4061-a383-daee6d30961a","acronym":"BMTCTN1902","url":"https://clinicaltrials.gov/study/NCT05032820","created_at":"2021-09-02T14:53:04.280Z","updated_at":"2025-02-25T14:16:18.481Z","phase":"Phase 2","brief_title":"MM CAR-T to Upgrade Response BMTCTN1902","source_id_and_acronym":"NCT05032820 - BMTCTN1902","lead_sponsor":"Marcelo Pasquini, MD","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • cyclophosphamide • fludarabine IV • Abecma (idecabtagene vicleucel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/05/2022","start_date":" 01/05/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-01-08"},{"id":"521b2a4d-03c6-4570-b1d2-4865cf348889","acronym":"CARTD-BG-1","url":"https://clinicaltrials.gov/study/NCT06097455","created_at":"2023-10-24T15:13:50.040Z","updated_at":"2024-07-02T16:35:31.681Z","phase":"Phase 1","brief_title":"First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma","source_id_and_acronym":"NCT06097455 - CARTD-BG-1","lead_sponsor":"Fundacion Clinic per a la Recerca Biomédica","biomarkers":" TNFRSF17","pipe":"","alterations":" ","tags":["TNFRSF17"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/15/2024","start_date":" 01/15/2024","primary_txt":" Primary completion: 04/15/2025","primary_completion_date":" 04/15/2025","study_txt":" Completion: 01/15/2027","study_completion_date":" 01/15/2027","last_update_posted":"2023-10-26"},{"id":"91129fdb-7ee9-4817-acf7-e8fc2da77a2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03338972","created_at":"2021-01-18T16:29:36.458Z","updated_at":"2025-02-25T14:37:39.553Z","phase":"Phase 1","brief_title":"Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT03338972","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" SDC1","pipe":" | ","alterations":" SDC1 expression","tags":["SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SDC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • FCARH143 • FHVH-BCMA-T • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 11/29/2017","start_date":" 11/29/2017","primary_txt":" Primary completion: 05/03/2021","primary_completion_date":" 05/03/2021","study_txt":" Completion: 03/22/2022","study_completion_date":" 03/22/2022","last_update_posted":"2023-09-08"},{"id":"4a700ab9-69ca-4c09-91fb-3f3d10c837b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05431608","created_at":"2022-06-24T15:56:46.509Z","updated_at":"2024-07-02T16:35:42.972Z","phase":"Phase 1","brief_title":"A Study of MCARH109 and MCARH125 in People With Multiple Myeloma","source_id_and_acronym":"NCT05431608","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" SDC1","pipe":"","alterations":" ","tags":["SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MCARH109 • MCARH125"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 06/20/2022","start_date":" 06/20/2022","primary_txt":" Primary completion: 06/20/2024","primary_completion_date":" 06/20/2024","study_txt":" Completion: 06/20/2024","study_completion_date":" 06/20/2024","last_update_posted":"2023-07-14"},{"id":"8e484efc-2bb4-4551-a333-691298e0bf81","acronym":"","url":"https://clinicaltrials.gov/study/NCT05767359","created_at":"2023-03-14T14:01:36.331Z","updated_at":"2024-07-02T16:35:45.349Z","phase":"Phase 2","brief_title":"CAR- PRISM (PRecision Intervention Smoldering Myeloma)","source_id_and_acronym":"NCT05767359","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • Chr t(4;14) • Chr t(14;16)","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr t(4;14) • Chr t(14;16)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Carvykti (ciltacabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/19/2023","start_date":" 04/19/2023","primary_txt":" Primary completion: 01/15/2026","primary_completion_date":" 01/15/2026","study_txt":" Completion: 01/15/2040","study_completion_date":" 01/15/2040","last_update_posted":"2023-06-19"},{"id":"13af71f1-2f6f-47c7-a8c9-9d697170772d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04272151","created_at":"2021-03-03T17:53:41.198Z","updated_at":"2024-07-02T16:35:50.362Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma","source_id_and_acronym":"NCT04272151","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCMA CAR-T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/01/2019","start_date":" 12/01/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-04-18"},{"id":"eb58053b-f171-4cc3-b6ba-2db156b2fb18","acronym":"","url":"https://clinicaltrials.gov/study/NCT04776330","created_at":"2021-03-03T14:56:37.677Z","updated_at":"2024-07-02T16:35:50.191Z","phase":"Phase 1/2","brief_title":"a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma","source_id_and_acronym":"NCT04776330","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCMA CAR-T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 03/07/2021","start_date":" 03/07/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-04-18"},{"id":"4cd00ace-eb77-4eb4-8c29-3d41b9d5e4fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05513612","created_at":"2022-08-24T21:07:38.118Z","updated_at":"2024-07-02T16:35:54.501Z","phase":"Phase 1","brief_title":"Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies","source_id_and_acronym":"NCT05513612","lead_sponsor":"Shanghai Pudong Hospital","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Autologous CAR-T cells"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/01/2020","start_date":" 08/01/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-03-01"},{"id":"745efccf-4213-4879-bbd4-a904c2add42c","acronym":"CARTIFAN-1","url":"https://clinicaltrials.gov/study/NCT03758417","created_at":"2021-01-18T18:28:26.452Z","updated_at":"2024-07-02T16:35:58.499Z","phase":"Phase 2","brief_title":"A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT03758417 - CARTIFAN-1","lead_sponsor":"Nanjing Legend Biotech Co.","biomarkers":" CD8 • IL6 • IL2RA • CD4 • IL10","pipe":"","alterations":" ","tags":["CD8 • IL6 • IL2RA • CD4 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Carvykti (ciltacabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 01/23/2019","start_date":" 01/23/2019","primary_txt":" Primary completion: 02/16/2026","primary_completion_date":" 02/16/2026","study_txt":" Completion: 02/16/2026","study_completion_date":" 02/16/2026","last_update_posted":"2022-12-28"},{"id":"dda9854f-608a-4827-82f0-c0985a5b7f59","acronym":"","url":"https://clinicaltrials.gov/study/NCT05594797","created_at":"2022-10-26T13:56:22.365Z","updated_at":"2024-07-02T16:35:59.318Z","phase":"Phase 2","brief_title":"Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM","source_id_and_acronym":"NCT05594797","lead_sponsor":"Hrain Biotechnology Co., Ltd.","biomarkers":" TNFA • IL2 • IL10 • CRP","pipe":"","alterations":" ","tags":["TNFA • IL2 • IL10 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anti-BCMA CAR-T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 07/12/2022","start_date":" 07/12/2022","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2022-12-09"},{"id":"dee45767-9e90-4e48-a60b-32ad585b3761","acronym":"","url":"https://clinicaltrials.gov/study/NCT05618041","created_at":"2022-11-16T19:57:24.637Z","updated_at":"2024-07-02T16:35:59.629Z","phase":"","brief_title":"The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies","source_id_and_acronym":"NCT05618041","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" CD8 • IL6 • CD4 • IL10","pipe":"","alterations":" ","tags":["CD8 • IL6 • CD4 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • senl_BCMA"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/07/2022","start_date":" 09/07/2022","primary_txt":" Primary completion: 09/06/2024","primary_completion_date":" 09/06/2024","study_txt":" Completion: 12/06/2024","study_completion_date":" 12/06/2024","last_update_posted":"2022-12-06"},{"id":"08b8122b-281e-4546-9d5c-29a377443acd","acronym":"GC012F-32","url":"https://clinicaltrials.gov/study/NCT04935580","created_at":"2021-06-23T18:52:53.726Z","updated_at":"2025-02-25T14:59:57.343Z","phase":"Phase 1/2","brief_title":"Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients","source_id_and_acronym":"NCT04935580 - GC012F-32","lead_sponsor":"Shanghai Changzheng Hospital","biomarkers":" IFNG • IL6 • IL10","pipe":"","alterations":" ","tags":["IFNG • IL6 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AZD0120"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/28/2021","start_date":" 06/28/2021","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 07/01/2023","study_completion_date":" 07/01/2023","last_update_posted":"2022-08-03"},{"id":"746c9607-ab29-4d33-b2b4-9e8c8d9066d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05201118","created_at":"2022-01-21T14:58:12.727Z","updated_at":"2024-07-02T16:36:09.998Z","phase":"Phase 1","brief_title":"A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma","source_id_and_acronym":"NCT05201118","lead_sponsor":"Chunrui Li","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor) • Fucaso (equecabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2022-05-24"},{"id":"15121b25-6844-4923-b564-1b27903b4d30","acronym":"","url":"https://clinicaltrials.gov/study/NCT05325801","created_at":"2022-04-13T11:55:04.792Z","updated_at":"2024-07-02T16:36:12.834Z","phase":"Phase 1","brief_title":"A Study of CAR-T Cells Targeting Both BCMA and GPRC5D in Treatment of Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT05325801","lead_sponsor":"Zhejiang University","biomarkers":" GPRC5D","pipe":"","alterations":" ","tags":["GPRC5D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BM-ca • OriC321"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2022-04-13"},{"id":"c12aca54-63c9-48f0-993a-2557e3534158","acronym":"FUMANBA-2","url":"https://clinicaltrials.gov/study/NCT05181501","created_at":"2022-01-06T22:53:41.226Z","updated_at":"2024-07-02T16:36:18.778Z","phase":"Phase 1","brief_title":"A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)","source_id_and_acronym":"NCT05181501 - FUMANBA-2","lead_sponsor":"Nanjing IASO Biotherapeutics Co.,Ltd","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fucaso (equecabtagene autoleucel)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2039","study_completion_date":" 04/01/2039","last_update_posted":"2022-01-06"},{"id":"046bd970-a819-491c-b309-6d96f8ea30b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03941626","created_at":"2021-01-19T18:01:10.172Z","updated_at":"2024-07-02T16:36:35.027Z","phase":"Phase 1/2","brief_title":"Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies","source_id_and_acronym":"NCT03941626","lead_sponsor":"Shenzhen BinDeBio Ltd.","biomarkers":" HLA-A • MSLN • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • MSLN positive • HLA-A positive","tags":["HLA-A • MSLN • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • MSLN positive • HLA-A positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • multi-target gene-modified CAR-T/TCR-T cell immunotherapy"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 05/01/2021","primary_completion_date":" 05/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2021-02-04"},{"id":"adf97ffe-a5ab-4c9c-b219-b9ac297c59f3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04447573","created_at":"2021-01-18T21:24:04.628Z","updated_at":"2024-07-02T16:36:40.602Z","phase":"","brief_title":"Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT04447573","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" IFNG • IL6 • TNFA • IL10","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • S1904 • senl_BCMA"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/30/2020","start_date":" 06/30/2020","primary_txt":" Primary completion: 08/30/2022","primary_completion_date":" 08/30/2022","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2020-09-29"},{"id":"5f223186-b7bf-4972-9362-db1059880282","acronym":"","url":"https://clinicaltrials.gov/study/NCT04412889","created_at":"2021-01-18T21:16:26.482Z","updated_at":"2025-02-25T14:59:09.320Z","phase":"Phase 1","brief_title":"A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM","source_id_and_acronym":"NCT04412889","lead_sponsor":"Hebei Yanda Ludaopei Hospital","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AZD0120"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-06-02"},{"id":"031439da-5f9c-460c-8c05-2a1c5a400206","acronym":"","url":"https://clinicaltrials.gov/study/NCT03638206","created_at":"2021-01-18T17:51:53.397Z","updated_at":"2024-07-02T16:36:52.614Z","phase":"Phase 1/2","brief_title":"Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies","source_id_and_acronym":"NCT03638206","lead_sponsor":"Shenzhen BinDeBio Ltd.","biomarkers":" MET • CD19 • HLA-A • MSLN • CD22 • CD33 • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • CD19 expression • HLA-A positive","tags":["MET • CD19 • HLA-A • MSLN • CD22 • CD33 • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • CD19 expression • HLA-A positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CAR-T cell immunotherapy • multi-target gene-modified CAR-T/TCR-T cell immunotherapy"],"overall_status":"Recruiting","enrollment":" Enrollment 73","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2019-12-11"}]